NCT01684111 - An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV (VENUS-1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

January 31, 2016

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

BIBF 1120

2 x 150 mg capsules, oral, daily (Start dose)

DRUG

Vinorelbine

25 mg/m2 i.v. on day 1 and 8 (three-week cycle)

Trial Locations (4)

LungenClinic Großhansdorf GmbH, Großhansdorf

Klinikum Kassel GmbH, Kassel

Thoraxklinik Universitätsklinikum Heidelberg, Heidelberg

Klinikum der Universität München, München